Dabur India Q4 Review - Health, Immunity, Ayurveda Trends To Continue: ICICI Direct
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Direct Report
Dabur India Ltd. reported 25.3% revenue growth in Q4 on account of the hit in the base quarter with lockdown imposed in the last 10 days of the March quarter.
Domestic sales grew 30.3% whereas international business saw 19.4% revenue growth.
India business volume growth was 25.4%. All categories saw robust growth.
Health supplements (Chyawanprash, Honey) sales grew 17.7% despite it being off-season for the products.
Over-the-counter and ethical continued the growth momentum with 34% and 39.1% growth, respectively.
Oral care grew 42.1% with red toothpaste gaining market share.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.